Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAK1 | Q13153 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.37 |
| ▸ | HTR4 | Q13639 | 2/20 | 0.36 |
| ▸ | HPGDS | O60760 | 1/20 | 0.36 |
| ▸ | KDM5A | P29375 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | PDE4A | P27815 | 1/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.34 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.34 |
| ▸ | MDM4 | O15151 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL985429 | 0.94 | PAK1 (0.38) | PAK1KMT2AHTR4HPGDSKDM5A | |
| SCHEMBL983643 | 0.91 | MDM4 (0.36) | PAK1KMT2AKDM5AMEN1L3MBTL1 | |
| SCHEMBL984887 | 0.91 | HPGDS (0.44) | PAK1KMT2AHTR4HPGDSMEN1 | |
| SCHEMBL982027 | 0.91 | BRD4 (0.37) | PAK1KMT2AKDM5AMEN1 | |
| SCHEMBL983742 | 0.90 | MCHR1 (0.35) | PAK1KDM5AMCHR1L3MBTL1TSHR | |
| SCHEMBL981821 | 0.90 | TBK1 (0.41) | PAK1KMT2AHTR4HPGDSMCHR1 | |
| SCHEMBL981830 | 0.90 | MTNR1B (0.40) | PAK1KMT2AHTR4HPGDSMCHR1 | |
| SCHEMBL984581 | 0.89 | ALDH1A1 (0.44) | KMT2AMEN1L3MBTL1TSHR | |
| SCHEMBL983552 | 0.89 | BTK (0.40) | PAK1KMT2AHTR4HPGDSMCHR1 | |
| SCHEMBL985290 | 0.89 | KDM5A (0.37) | PAK1KMT2AKDM5AMDM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110021479-A1 | PYRROLOPYRIMIDINECARBOXAMIDES | NYCOMED GMBH (DE) | 2011-01-27 | — | — | US | claimed |
| US-20110021479-A1 | PYRROLOPYRIMIDINECARBOXAMIDES | NYCOMED GMBH (DE) | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021479-A1 | PYRROLOPYRIMIDINECARBOXAMIDES | PDE5A, PDE3A, PDE2A | PAK1 1999/4885KMT2A 2975/4885HTR4 1818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.